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Abstract
Background:  Cytochrome P450 monoxygenases play an important role in the defence against
inhaled toxic compounds and in metabolizing a wide range of xenobiotics and environmental
contaminants. In ambient aerosol the ultrafine particle fraction which penetrates deeply into the
lungs is considered to be a major factor for adverse health effects. The cells mainly affected by
inhaled particles are lung epithelial cells and cells of the monocyte/macrophage lineage.
Results: In this study we have analyzed the effect of a mixture of fine TiO2 and ultrafine carbon
black Printex 90 particles (P90) on the expression of cytochrome P450 1B1 (CYP1B1) in human
monocytes, macrophages, bronchial epithelial cells and epithelial cell lines. CYP1B1 expression is
strongly down-regulated by P90 in monocytes with a maximum after P90 treatment for 3 h while
fine and ultrafine TiO2 had no effect. CYP1B1 was down-regulated up to 130-fold and in addition
CYP1A1 mRNA was decreased 13-fold. In vitro generated monocyte-derived macrophages (MDM),
epithelial cell lines, and primary bronchial epithelial cells also showed reduced CYP1B1 mRNA
levels. Benzo[a]pyrene (BaP) is inducing CYB1B1 but ultrafine P90 can still down-regulate gene
expression at 0.1 μM of BaP. The P90-induced reduction of CYP1B1 was also demonstrated at the
protein level using Western blot analysis.
Conclusion: These data suggest that the P90-induced reduction of CYP gene expression may
interfere with the activation and/or detoxification capabilities of inhaled toxic compounds.
Background
Several epidemiologic studies attribute increased morbid-
ity and mortality to exposure to environmental particles
[1-3]. These adverse health effects due to the inhalation of
particulate matter are a topic of ongoing scientific and
public concern. Particulate matter (PM) is a complex mix-
ture of many different components, which can be charac-
terized by origin (anthropogenic or geogenic), by
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physicochemical properties (such as solubility) or by par-
ticle size. Particles with a mean aerodynamic size between
10 and 2.5 μm (PM10) are classified as coarse particles,
fine particles have a size between 2.5 and 0.1 μm and par-
ticles with a diameter less than 0.1 μm are termed
ultrafine. Not only the particle size but other particle-asso-
ciated parameters like particle number, surface area or
reactive compounds adsorbed to the surface may be
involved in the observed health effects [4]. Because of
their small size, ultrafine particles contribute only mod-
estly to total mass, but they are the predominant fraction
by number in PM. Most urban particles result from com-
bustion processes, therefore the major fraction contains
ultrafine carbonaceous particles [5]. After deposition in
the lung larger particles are phagocytized by alveolar and
airway macrophages [6,7], but the fine and ultrafine car-
bon particles remain in the lung for a longer period of
time [5]. Ultrafine particles are phagocytized to a minor
extend but they can still enter macrophages and epithelial
cells and even penetrate into the circulation. Thus
ultrafine particles not only trigger local inflammatory
reactions in the lung but also cause systemic extrapulmo-
nary effects [8]. Ultrafine particles also have the capacity
to inhibit phagocytosis by alveolar macrophages [9]. Mac-
rophages and their monocyte progenitors are major ele-
ments of the inflammatory response. In addition to
performing phagocytosis they can release inflammatory
mediators such as cytokines and chemokines and they are
crucially involved in destruction of microbes and particles
using various enzymatic systems [10]. Cytochromes like
CYP1B1  are also expressed by macrophages and these
enzymes are part of the "digestive" and detoxifying
machinery of these cells [8].
The xenobiotic metabolism can be divided into two
phases: modification (phase I) and conjugation (phase
II). An important group of phase I enzymes consists of the
cytochrome P450 oxidases (CYP) which belong to the mon-
oxygenases. In humans 57 CYPs are known and about
25% of them are considered to be involved primarily in
the xenobiotic metabolisms [11]. Superfamily members
are classified according to the similarity of their primary
structure. The expression of the CYP1 subfamily can be
induced by polycyclic aromatic hydrocarbons (PAH),
which are ubiquitously occuring environmental carcino-
gens [12] and are particularly known to be present in cig-
arette smoke [13]. The induction of CYP1  genes is
regulated by a heterodimer of the aryl hydrocarbon recep-
tor (AhR) and the aryl hydrocarbon receptor nuclear
translocator (Arnt) [14]. Two cytochromes, CYP1A1 and
CYP1B1, are mainly involved in the formation of ultimate
carcinogenic diol-epoxides of PAH such as
benzo[a]pyrene (BaP) [15]. The expression of these
enzymes is largely extrahepatic and both enzymes are
present in many tumor tissues [16,17]. CYP1B1 has been
identified as a major P450 enzyme in normal human
blood monocytes [18] and CYP1B1  is also present in
human lung and lung-derived cell lines [19].
Monocytes, macrophages and epithelial cells are affected
by particles. CYP1B1 is involved in both, detoxification as
well as metabolic activation of xenobiotics [12]. Thus it is
important to address the question of whether and in what
way particles affect CYP1B1. This study is aimed on the
effects of carbon particles on the expression of CYP1B1 in
monocytes/macrophages and bronchial epithelial cells
and we demonstrate a pronounced down-regulation of
mRNA expression and protein level of this important ext-
rahepatic enzyme.
Results
Effect of particle exposure on CYP1B1 mRNA expression
In earlier experiments using gene expression arrays, we
noted a decreased expression of CYP1B1 mRNA in mono-
cyte-derived macrophages (MDM) of patients with COPD
(http://www.ncbi.nlm.nih.gov/geo/; accession number
GSE8608). Since exposure of particles plays a major role
in the etiology of this disease, we studied the effect of par-
ticles on cells of the monocyte/macrophage lineage. To
cover a wider range of particle materials (chemistry) and
their physical properties (size, surface structure) and
because of economical reasons (cost-effectiveness) we ini-
tially used a mixture of both particles, ultrafine P90 (mean
size 90 nm) and fine TiO2 (mean size 200 nm). We ana-
lyzed the effect of this mixture on CD14++ monocytes
after 3h of exposure.
Expression levels were calculated relative to correspond-
ing mRNA level for α-enolase in the same sample, such
that negative values indicate a transcript prevalence that is
less than that of α-enolase in the same cell population. As
shown in Fig. 1A, incubation of CD14++ monocytes with
this mixture of ultrafine P90 and fine TiO2 resulted in a
pronounced decrease of CYP1B1  mRNA transcripts (-
4,308 ± 2,231) reflecting a 95-fold reduction compared to
untreated cells (-45 ± 37). LPS showed a minor effect with
respect to CYP1B1 expression (-68 ± 41).
We then addressed the question which of the two types of
particles in the mixture caused the down-regulation of
CYP1B1 mRNA in CD14++ monocytes. As shown in Fig.
1A the decrease of CYP1B1 transcripts can be attributed to
ultrafine P90 alone which reduced expression 136-fold to
a level of -6,109 ± 1,759, while the fine TiO2 showed no
effect (-50 ± 21) compared to untreated cells (-45 ± 37).
Since the down-regulation of CYP1B1 is only found in
P90 we next asked whether this was due to the ultrafine
nature of the particle. We therefore tested ultrafine TiO2
but found no activity with an expression level of -34 ± 20
in untreated and of -27 ± 18 in treated PBMC (n = 3; data
not shown). Hence low size is not sufficient a feature toParticle and Fibre Toxicology 2009, 6:27 http://www.particleandfibretoxicology.com/content/6/1/27
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explain the effect on CYP1B1. Other properties found in
P90 and not in TiO2 appear to be responsible.
CYP1A1 is a cytochrome monoxygenase closely related to
CYP1B1, so we asked whether expression of this gene is
also influenced by particles. Incubation of CD14++
monocytes with ultrafine P90 for 3 h led to a pronounced
13-fold down-regulation of CYP1A1  mRNA (-12,204 ±
5,622). No effect of LPS (-1,508 ± 781) or fine TiO2 (-
1,013 ± 746) was detected when compared to untreated
cells (-940 ± 823) (Fig. 1B). These data show that CYP1A1
is also affected by ultrafine P90 albeit to a lesser extent
compared to CYP1B1.
Exclusion of LPS-contamination of particles
A frequent problem in cell biology is LPS-contamination
of materials including particles such as those used in our
experiments. While in our system LPS alone had a minor
effect on its own, we still needed to exclude a contribution
of this compound when combined with particles. For this
we used Polymyxin B, a compound which is known to
inhibit pro-inflammatory signals induced by LPS [20].
Polymyxin B on its own did not alter mRNA expression of
CYP1B1 (-10 ± 3) compared to untreated cells (-12 ± 4). It
did suppress however the moderate LPS-induced decrease
of CYP1B1 mRNA from -24 ± 10 to -13 ± 9 (p < 0.05). On
the other hand the P90-induced down-regulation of
expression of CYP1B1 mRNA (-1,292 ± 1,031) was not
altered by Polymyxin B (-945 ± 935) (not significant, Fig.
2). These findings support the assumption that particles
are not contaminated by LPS.
Dose response and time course of P90-induced CYP1B1 
mRNA repression
To determine optimum dose of ultrafine carbon particles
for cytochrome monoxygenase 1B1 mRNA repression we
incubated CD14++ monocytes with or without different
doses of P90 for 3 h. Subsequently CYP1B1 mRNA levels
were detected (Fig. 3A). The effects were significant even
at low doses, starting with 0.32 μg/ml (-18 ± 8), followed
by 3.2 μg/ml (-69 ± 41). A more pronounced decrease of
CYP1B1 transcripts was seen at 32 μg P90/ml (-1,152 ±
882, 96-fold reduction), at 320 μg P90/ml (2192 ± 1173,
183-fold reduction) and at 1,000 μg/ml (-2,814 ± 1,754,
235-fold reduction). To exclude a toxic effect on cells
incubated with the high particle concentrations, a trypan
blue viability test was performed. It showed no decrease of
cell viability at all particle concentrations. Levels of α-eno-
lase mRNA also gave no evidence of loss of viability of
these cells (data not shown). For all further experiments
we used a particle concentration of 32 μg/ml dose.
Next we analyzed the time course of CYP1B1  mRNA
repression (Fig. 3B). CD14++ monocytes were incubated
with P90 at 32 μg/ml from 0.5 h to 20 h. Repression of
CYP1B1 was detectable after 0.5 h incubation (-27 ± 2),
was more pronounced after 1 h (-89 ± 18) and reached a
plateau after 3 and 6 h (-1,856 ± 605 116-fold reduction,
and -1,766 ± 584, 110-fold reduction, respectively). After
20 h CYP1B1 mRNA levels recovered but were still 46-fold
reduced (-740 ± 275) compared to untreated cells. Based
A) Effect of LPS, ultrafine P90, and fine TiO2 on CYP1B1  mRNA levels in CD14++ monocytes Figure 1
A) Effect of LPS, ultrafine P90, and fine TiO2 on 
CYP1B1 mRNA levels in CD14++ monocytes. Cells 
were purified from PBMC of healthy donors by MACS sepa-
ration. CD14++ cells remained untreated (none) or were 
stimulated with LPS (10 ng/ml), with particle-mix of ultrafine 
P90 and fine TiO2 (each with 32 μg/ml) or with each particle 
separately for 3 h. Cells were lysed and mRNA levels were 
determined by RT-PCR. Data were normalized to levels of 
the house keeping gene α-enolase. (n = 3 incubations from 
different donors, mean ± S.D.; * p < 0.05 compared to 
untreated controls). B) Down-regulation of CYP1A1 mRNA 
in monocytes. CD14++ cells remained untreated (none) or 
were stimulated with LPS (10 ng/ml), with particle-mix of 
ultrafine P90 and fine TiO2 (each with 32 μg/ml) or with each 
particle separately for 3 h. Cells were lysed and mRNA levels 
were determined by RT-PCR. (n = 3 incubations from differ-
ent donors, mean ± S.D.; * p < 0.05 compared to untreated 
controls).
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on this analysis we used the 3 h time point for all further
experiments.
Effect of particles on CYP1B1 and CYP1A1 mRNA 
expression in MDM from healthy donors and COPD 
patients
MDMs are more mature than monocytes and might show
an effect of ultrafine P90 on CYP1B1 expression different
from what is seen in monocytes. We therefore matured
freshly isolated CD14++ monocytes with M-CSF at 100
ng/ml for 5 days and subsequently treated the cells with
32 μg P90/ml for 3 h (Fig. 4A). We used cells from healthy
donors and COPD patients to address the question
whether these patients have an altered capacity to deal
with exogenous particulates.
In untreated MDM of healthy donors a basal mRNA
expression of CYP1B1 was at -40 ± 40. After LPS stimula-
tion CYP1B1 transcript was reduced by factor 2.6 (-105 ±
114, Fig. 4A). Stimulation with the particle-mix of
ultrafine P90 and fine TiO2 led to a 2.7-fold reduction of
CYP1B1  mRNA (-109 ± 87, Fig. 4A). Untreated MDM
from COPD patients showed a higher level of CYP1B1
mRNA (-27 ± 11) and a 2-fold decrease in CYP1B1 tran-
script after incubation with particles (-56 ± 21, Fig. 4A).
Looking at CYP1A1  expression in the same MDM we
noted a much lower level or constitutive expression com-
pared to CYP1B1. In healthy donors CYP1A1  mRNA
expression was -19,350 ± 17,811, after LPS and particle
treatment 1A1 transcript levels were -84,195 ± 49,677 (4-
fold) and -55,720 ± 96,911 (3-fold) respectively. In MDM
of COPD patients 1A1  mRNA levels were -66,840 ±
59,479 in untreated cells and -83,509 ± 66,575 in particle-
treated cells (not significant; data not shown).
Particle induced down-regulation of CYP1B1 is not due to  contaminant LPS Figure 2
Particle induced down-regulation of CYP1B1 is not 
due to contaminant LPS. CD14++ monocytes remained 
untreated (none) or were stimulated with LPS (10 ng/ml) and 
ultrafine P90 (32 μg/ml) each with and without 15 min Poly-
myxinB preincubation to suppress the LPS effect. After incu-
bation for 3 h cells were lysed and mRNA levels were 
determined by RT-PCR (n = 6 incubations from different 
donors, mean ± S.D.; * p < 0.05 compared to untreated 
cells).
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A) Dose response analysis of ultrafine P90-induced down- regulation of CYP1B1 Figure 3
A) Dose response analysis of ultrafine P90-induced 
down-regulation of CYP1B1. CD14++ cells remained 
untreated (0 μg/ml) or were stimulated with various doses of 
0.32 μg/ml - 1 mg/ml of ultrafine P90 for 3 h. mRNA was 
recovered and levels of CYP1B1 mRNA were determined by 
RT-PCR (n = 5 incubations from different donors, mean ± 
S.D.; * p < 0.05 compared to 0 μg/ml). B) Time course of 
ultrafine P90-induced down-regulation of CYP1B1. CD14++ 
monocytes were stimulated for 0, 0.5, 1, 2, 3, 6 and 20 h with 
ultrafine P90 (32 μg/ml) (n = 3 incubations from different 
donors, mean ± S.D.; * p < 0.05 compared to 0 h).
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A) MDM were generated from CD14++ monocytes purified from PBMC by MACS separation followed by 5-day incubation  with M-CSF (100 ng/ml) Figure 4
A) MDM were generated from CD14++ monocytes purified from PBMC by MACS separation followed by 5-
day incubation with M-CSF (100 ng/ml). Cells remained untreated (none) or were stimulated with LPS (10 ng/ml) or with 
particle-mix of ultrafine P90 and fine TiO2 (each with 32 μg/ml) for 3 h (n = 5 patients with COPD, n = 8 healthy controls, 
mean ± S.D.; * p < 0.05 compared to untreated controls). B) Effect of particles on CYP1B1 expression in sputum macrophages 
of healthy non-smokers, healthy smokers and patients with COPD. Sputum macrophages were purified using RosetteSep to 
deplete unwanted leukocytes. Cells remained untreated (none) or were stimulated with LPS (10 ng/ml) or with particle-mix of 
ultrafine P90 and fine TiO2 (each with 32 μg/ml) for 3 h (n = 5 non-smokers, n = 4 smokers, n = 7 patients with COPD, mean 
± S.D.; * p < 0.05). C) Cells remained untreated (none) or were stimulated with LPS (10 ng/ml), with particle mix of ultrafine 
P90 and fine TiO2 (each with 32 μg/ml) or with each particle separately for 22 h (each with 32 μg/ml) (A549 n = 3, Calu-3 n = 
4 experiments from different cell passages, mean ± S.D.; * p < 0.05 compared to untreated control). D) Effect of ultrafine P90 
on CYP1B1 mRNA expressin in primary bronchial epithelial cells. Cells were obtained by bronchial brush biopsy. Cells 
remained untreated (none) or were stimulated with ultrafine P90 (32 μg/ml) for 3 h (n = 7 incubations from different donors, 
mean ± S.D.; * p < 0.05 compared to untreated control).
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Taken together MDMs when compared to blood mono-
cytes do show a decrease of cytochrome monoxygenases
but the effect appears to be less pronounced with respect
to CYP1B1 and CYP1A1.
Effect of particles on CYP1B1 mRNA expression in 
sputum macrophages from non-smokers, smokers, and 
COPD patients
Macrophages in the airways are exposed to inhaled parti-
cles and this may impact on CYP expression. We therefore
isolated macrophages from induced sputum of healthy
non-smokers, healthy smokers and COPD patients (6 ex-
smokers and one current smoker). In healthy non-smok-
ers particles reduced CYP1B1 expression in sputum mac-
rophages 2.8-fold (-530 ± 547) compared to untreated
cells (-191 ± 198) (Fig. 4B). In COPD expression of
CYP1B1  was at -90 ± 97. Treatment of COPD sputum
macrophages for 3 h with ufP90/fTiO2 led to a 2.7-fold
decrease of CYP1B1 transcripts (-247 ± 346) compared to
3 h untreated cells. The single currently smoking patient
showed the highest mRNA expression of CYP1B1 (-22)
with no decrease of transcript after ultrafine P90/fine TiO2
stimulation (-29).
When looking at healthy smokers we found a very high
expression level for CYP1B1 (-18 ± 15). Incubation with
the particle mixture for 3 h had no effect on CYP1B1 tran-
scripts of smokers (-16 ± 13) compared to untreated cells
(Fig. 4B). These data show that in smokers sputum macro-
phages are refractory to the action of particles.
Effect of particles on CYP1B1 mRNA expression in human 
epithelial cells
Inhaled particles also deposit on alveolar epithelial cells.
We thus investigated the effect of ultrafine P90 and fine
TiO2 on CYP1B1 mRNA expression in the human alveolar
epithelial cell line A549 and a bronchial epithelial cell
line Calu-3. In these experiments we used an incubation
time of 22 h as a preliminary time point, which afterwards
was optimized depending on cell type (primary cells or
cell line) and read-out (transcript or protein analysis).
Compared to untreated A549 cells (-158 ± 73) CYP1B1
mRNA levels were decreased after 22 h incubation with
P90 by factor 4 (-707 ± 347, p < 0.05) (Fig. 4C). LPS (-206
± 81) treatment shows no effect, whereas a slight effect
was observed with fine TiO2 (-287 ± 134) treatment. In
cells incubated with both ultrafine P90 and fine TiO2,
CYP1B1 transcript levels were decreased to -948 ± 507.
In the bronchial epithelial cell line Calu-3 the expression
of CYP1B1 in untreated cells was 301 ± 140 (Fig 4C).
Ultrafine P90- (-2,820 ± 1,546) and ultrafine P90/fine
TiO2-treated cells (-3,106 ± 1,988) showed a strong 10-
fold decrease of CYP1B1 mRNA. LPS (-360 ± 147) and
fine TiO2 (-297 ± 144) showed no effect.
To confirm the results of epithelial cell lines we investi-
gated the effects of P90 on CYP1B1 mRNA expression in
primary bronchial epithelial cells. Cells were obtained by
bronchial brush and treated with and without 32 μg
ultrafine P90/ml for 3 h. As shown in Fig. 4DCYP1B1 tran-
script levels were reduced 4-fold in ultrafine P90-treated
cells (-1,163 ± 1,161) compared to untreated cells (-267 ±
373). This included two cases with a very strong response
(35- and 14-fold). Hence primary epithelial cells can be
very sensitive to the action of ultrafine carbon particles.
Effect of benzo[a]pyrene on CYP1B1 mRNA expression in 
human peripheral blood mononuclear cells (PBMC)
Cytochrome P450 enzymes are known to be involved in
the metabolism of polycyclic aromatic hydrocarbons
(PAH). Benzo[a]pyrene (BaP), a carcinogenic representa-
tive of this class of compounds, strongly up-regulated
CYP1B1 mRNA levels in PBMC. Time course experiments
showed an increase in transcripts from -88 ± 20 in
untreated cells to -6 ± 2 in cells after 3 h, and -4 ± 2 after
6 h incubation with BaP (data not shown).
To investigate whether BaP is capable of overcoming the
repression of CYP1B1 induced by P90, PBMC were either
pre-incubated with ultrafine P90 particles (32 μg/ml) or
remained untreated. After 30 min of incubation, BaP-con-
Interference between ultrafine P90 and benzo[a]pyrene  (BaP) in CYP1B1 induction in PBMC Figure 5
Interference between ultrafine P90 and 
benzo[a]pyrene (BaP) in CYP1B1 induction in PBMC. 
Cells remained untreated or pre-stimulated with ultrafine 
P90 (32 μg/ml) for 30 min. Subsequently cells were stimu-
lated with liposomes containing three different concentra-
tions of BaP (0.1 μM, 1 μM, and 10 μM) and incubated for 3 
h. (n = 7 incubations from different donors, mean ± S.D.; * p 
< 0.05 compared to untreated control).
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taining liposomes were added in different concentrations
(0.1 to 10 μM) (Fig. 5).
CYP1B1 mRNA in untreated cells (-29 ± 18) was decreased
by ultrafine P90 treatment (-1,178 ± 1,011), on the other
hand BaP induced this gene (0.1 μM: -11 ± 4.2; 1 μM: -8.5
± 3.7; 10 μM: -8.1 ± 3.8). While at high BaP concentra-
tions (1 and 10 μM), ultrafine P90 could not reduce
CYP1B1 mRNA, it was able to suppress the transcripts by
factor 7 at 0.1 μM BaP (p < 0.05).
Effect of P90 on CYP1B1 protein levels in Calu-3
To investigate CYP1B1 protein levels we performed West-
ern blot analysis with isolated microsomal protein of
Calu-3 cells. In the blot shown in Fig. 6, the densitometric
reading for CYP1B1 protein in Calu-3 decreased from
3,036,276 AU (untreated cells, 32 h) to 373,799 AU after
ultrafine P90-treatment for 32 h. In average of 3 experi-
ments CYP1B1 protein level in untreated cells was
2,721,541 ± 379,059 AU and P90 treatment reduced this
to 342,109 ± 46,303 AU (Fig. 6). CYP1B1 mRNA levels
analyzed at the same time point (32 h) and in the same
cells used for Western blotting showed a decrease of tran-
script for ultrafine P90-treated cells (-314 ± 144) com-
pared to untreated cells (-3,551 ± 1,889; p < 0.05) (Fig. 6,
right panel).
These data show that P90 will lead to a pronounced reduc-
tion of CYP not only at the mRNA but also at the protein
level.
Discussion
The data of this study show that P90 causes a strong
down-regulating effect on the CYP1B1 expression. Cyto-
chrome P450 monooxygenases are involved in detoxifica-
tion and toxification of xenobiotic substances.
Toxification is caused by metabolic transformation of non
or less toxic precursors into reactive intermediates. Cells
may thus be influenced by two mechanisms/modes of
action, they may either be protected or they may become
more susceptible to other inhaled substances by exposure
to ultrafine P90.
The strongest down-regulation of CYP1B1 expression after
stimulation with particle mix of ultrafine P90 and fine
TiO2 was observed in monocytes (60-fold, Fig. 1A). It is
unclear at this point why CYP1B1 is so much more sensi-
tive to P90 effects than CYP1A1 (Fig. 1B). Whether this is
determined at the promoter level needs to be addressed in
the future. As P90 was identified as the active component
in the particle mix (Fig. 1A) we addressed two questions.
The first question was, whether ultrafine TiO2 particles
were capable to show such strong down-regulation of
CYP1B1 mRNA expression as seen with ultrafine P90. To
study if the strong P90 effect is triggered by its ultrafine
nature (12 nm in diameter, specific surface area of 300
m2/g), we incubated cells with ultrafine TiO2 with a diam-
eter of 20 nm and a specific surface area of 48 m2/g [5].
Neither fine nor ultrafine TiO2 treatment did alter CYP1B1
mRNA expression. Beck-Speier et al. have shown a highly
significant correlation between the PGE2/TXB2 formation
and the specific particle surface area but not the mass con-
centration [21]. The smaller surface area of ultrafine TiO2
could be an explanation for the weaker effect of ultrafine
TiO2 (48 m2/g) compared to ultrafine P90 (300 m2/g).
Also the chemical composition or surface structure of the
particles may contribute to their reactivity towards various
Western blot analysis of ultrafine P90 effect on CYP1B1 protein in the human lung epithelial cell line Calu-3 Figure 6
Western blot analysis of ultrafine P90 effect on CYP1B1 protein in the human lung epithelial cell line Calu-3. 
Calu-3 cells were treated 32 h with or without P90 (32 μg/ml). Microsomal protein was isolated and the 57 kDa CYP1B1 pro-
tein was detected by a rabbit polyclonal antibody (CYP1B11-A, Alpha Diagnostic). Shown is a representative experiment out of 
three independent experiments. The right diagram shows the average CYP1B1 mRNA expression in Calu-3 cells after 32 h P90 
treatment (n = 3, mean ± S.D.; * p < 0.05 compared to untreated cells).
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cell types. Dick et al. [22] found for ultrafine TiO2 and
ultrafine P90 purchased from the same manufacturer and
with the same composition and surface area than those
used herein, different effects in mice when instilled into
the lungs. Ultrafine P90 exhibited a higher effect in influx
of neutrophile granulocytes into the lungs, higher mem-
brane damage (causes release of G-glutamyl transferase),
and higher levels of macrophage inflammatory protein 2
(MIP-2) in the lavage fluid 48 h after instillation than for
ultrafine TiO2.
Secondly we addressed the question, whether the
observed effect was caused by an LPS contamination of
P90. LPS contamination can be excluded by neutralizing
LPS with Polymyxin B. Our experiments with Polymyxin
B showed clearly that the down-regulation of CYP1B1 is
caused by ultrafine P90 and not by a potential endotoxin
contamination of the carbon black particles (Fig. 2). The
LPS-mediated reducing effect on CYP1B1  expression
could be abolished by Polymyxin B, whereas the P90
effect was not altered by Polymyxin B treatment.
With increasing concentrations of ultrafine P90 the
decrease of CYP1B1 expression becomes stronger. Each of
the observed effects was significant. Therefore the P90
concentration of 32 μg/ml was used for all further experi-
ments. The concentration of 32 μg/ml is in accordance
with environmentally relevant particle concentration.
Higher concentrations do not reflect realistic physiologi-
cal conditions [23].
We confirmed the reduced CYP1B1 mRNA-expression in
additional cell types. In MDM (Fig. 4A) we observed a 2.7-
fold decrease of CYP1B1 after particle treatment. In spu-
tum macrophages of healthy non smokers (Fig. 4B) we
showed a 4-fold and of COPD patients a 3-fold reduction
of CYP1B1. One of the COPD patients currently smoked
and showed a high level of CYP1B1 mRNA in untreated
sputum macrophages that was not affected after ultrafine
P90 treatment. Additionally in healthy smokers no effect
of particle treatment on CYP1B1  transcript level was
detected. This may be due to the high concentration of
organic compounds, e.g. polycyclic aromatic hydrocar-
bons (PAH), in cigarette smoke which in turn induced
CYP1B1 mRNA expression in a competitive manner. A
competitional behavior between induction of CYP1B1
mRNA by benzo[a]pyrene (BaP), a carcinogenic constitu-
ent of tobacco smoke [24], and decrease of CYP1B1 tran-
script by ultrafine P90 was clearly shown herein (Fig. 5).
Also these findings may suggest that monocytes become
less sensitive to ultrafine P90 treatment during matura-
tion, maybe because of a stronger signal transduction or
better uptake of particles in monocytes. In parallel to the
lower response to particles, sputum macrophages showed
no response to LPS with respect to down-regulation of
CYP1B1.
Epithelial cells are also affected by particle exposure. In
epithelial cell lines (Fig. 4C) we observed significant
down-regulation of CYP1B1 after ultrafine P90 stimula-
tion. Primary epithelial cells obtained by bronchial brush
(Fig. 4D) showed in average a 4-fold reduction of CYP1B1
mRNA with strong reductions (35- and 14-fold) in two
samples. To exclude a leukocyte contamination we ana-
lyzed the cells by flow cytometry and microscopic cell dif-
ferentiation. The stronger effects seen in two of the seven
samples may be due to the inter-individual variation or
may be due to the different clinical conditions and medi-
cations. Taken together there was no apparent clinical fea-
ture (diagnosis, medication, smoking status) to explain
the higher responses of bronchial epithelial cells in the
two cases.
To confirm the CYP1B1 mRNA down-regulation on pro-
tein level, we isolated the microsomal fraction, because
CYP1B1 is bound to the endoplasmatic membrane. It was
not possible to isolate sufficient numbers of primary cells
in order to obtain enough protein for Western blotting.
Therefore for Western blot we used the bronchial epithe-
lial cell line Calu-3 as a model cell line because they also
show a decrease in CYP1B1 transcripts at mRNA level after
ultrafine P90 exposure. The strongest reduction of
CYP1B1 mRNA was seen after 22 h, therefore we incu-
bated Calu-3 cell with P90 for 32 h to investigate protein
expression. Densitometric analysis of the Western blots
confirmed a reduction of CYP1B1 protein following P90
treatment (Fig. 6). We assume that also in monocytes and
macrophages CYP1B1 protein will be decreased substan-
tially, similar to the mRNA reduction in these cells.
When alveolar macrophages, monocytes, and airway epi-
thelial cells are exposed to particles, they are phagocytized
by these cell types [25,26] and can subsequently interfere
with gene expression or cell functions. For cells of the
monocytic lineage, one possibility is a transport mecha-
nism of particles via the macrophage receptor with colla-
genous structure (MARCO). In a study of Kanno et al. an
association between the uptake of fine and ultrafine parti-
cles and MARCO was shown [27]. In our study we
blocked the MARCO receptor with antibodies. The reduc-
tion of CYP1B1 transcripts after ultrafine P90 treatment
was not altered by blocking antibodies compared to iso-
type controls (data not shown). Accordingly the transport
mechanism of ultrafine P90 particles appears not to be
based on the MARCO receptor and the mechanism
involved is still elusive.
Transcription of CYP1B1 and CYP1A1 genes is regulated
by the interaction between PAH and the cytosolic arylhy-
drocarbon receptor. Dioxin is the most potent agonist
[17], but also BaP can activate the receptor complex [28].
Cigarette smoke and diesel soot contain a huge amount of
PAH adsorbed to particles [29,30]. Herein we showed aParticle and Fibre Toxicology 2009, 6:27 http://www.particleandfibretoxicology.com/content/6/1/27
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BaP-mediated induction of CYP1B1 in a concentration-
dependent manner (Fig. 5). Simultaneously treatment
with ultrafine P90 attenuates the CYP1B1 induction. The
attenuation may be less pronounced with low concentra-
tion of BaP (0.1 μM) because of absorption effects of BaP
onto P90 particles, which reduce the amount of bioavail-
able BaP. Overall these findings indicate a competing
behaviour of BaP and P90. In case of low BaP concentra-
tions (0.1 μM), P90 still reduces CYP1B1 expression and
this may affect its detoxifying/toxifying activity.
Besides CYP-gene products, myeloperoxidase (MPO) was
reported to play an important role in metabolic activation
of chemical carcinogens [31]. MPO catalyzes the conver-
sion of H2O2 into hypochlorous acid (HOCl), which is a
very strong oxidant and which in turn may be responsible
for the metabolic activation of inhaled chemicals or
organic compounds on inhaled particles. In our investiga-
tions we screened CD14++ monocytes for expression of
MPO on mRNA level after exposure to particles (Printex
90 and fine TiO2). Compared to resting monocytes (-
641), particle incubation (3 h) decreased MPO  mRNA
expression 4-fold (-2,662; not significant) (data not
shown). This result indicates that particles alter the expres-
sion of a broader variety of enzymes which are involved in
inflammation and the metabolism of xenobiotics. Little is
known about the mechanisms and specificity of this inter-
action and further investigations addressing this question
will be needed.
Also cytokines modulate CYP-gene expression. P90-
induced transcription factor NF-κB in alveolar macro-
phages leads to expression of pro-inflammatory cytokines
like TNF, IL-6, and IL-1β [32]. TNF in turn increases the
expression of CYP1B1  [33]. Umannová et al. report of
TNF-induced increase of CYP1B1 mRNA expression and
simultaneously suppression of BaP-induced CYP1A1
expression [34]. This dysregulation was found to be asso-
ciated with an enhanced formation of DNA adducts and
enhanced genotoxic effects.
CYP-expression is also regulated by aryl hydrocarbon recep-
tor (AhR) and AhR nuclear translocator (Arnt). Wu et al.
[35] discussed the reduction of AhR- and Arnt-expression
as the underlying mechanism for TNF-induced decrease of
CYP1A2 expression after LPS-treatment. In our system no
influence of particles was detected on AhR and Arnt on
transcriptional level (data not shown).
While a lot is known about induction of CYP-genes little
information is available on suppression of these genes by
particles. We show herein an unexpected and pronounced
reduction of CYP  expression in various cell types. The
reduction of CYP protein may lead to disruption of vari-
ous cellular functions: pathophysiological response to
stress signals (toxic substances or inflammation), an
adaptive homeostatic response (controlled generation of
reactive oxygen species) or a part of tightly regulated phys-
iological pathway (production of bile acid) [36]. Inflam-
matory mediators can be responsible for a reduction of
CYP mRNA [37]. Ke et al. reported that one mechanistic
explanation for LPS and cytokine-mediated CYP reduc-
tion may be an interaction with NFκB [38].
The reduction of CYP1B1  after ultrafine P90 treatment
could be a form of protective mechanism concerning oxi-
dative stress. Reactive oxygen species (ROS) generated by
CYP-catalyzed metabolisms can cause oxidative stress in
cells [39]. Reduced CYP1B1 may prevent further DNA
damage being caused by ROS. Furthermore, decreased
availability of CYP1B1 enzyme leads to a lesser activation
of PAH to reactive metabolites which otherwise could
cause DNA damage and cancer development [12]. On the
other hand CYP1B1 and CYP1A1 are also important for
detoxifying various xenobiotics. A reduced expression of
these cytochromes in monocytes/macrophages and lung
epithelial cells induced by inhaled carbon particles may
lead to increased damage by xenobiotics because of the
lack of its detoxifying character. Further investigations will
be required to elucidate by which mechanism the particles
affect the CYP1B1 expression.
Methods
Cell lines and culture medium
The epithelial cell lines A549 [40] and Calu-3 [41] were
cultured in Dulbecco's minimal essential medium NUT
mix F12 (21331-020, Invitrogen, Karlsruhe, Germany),
containing 10% FCS (S0115, Biochrom, Berlin, Ger-
many), L-glutamine 2 mM (15140-114, Invitrogen, Karl-
sruhe, Germany), and penicillin 200 U/ml/streptomycin
200 μg/ml (15140-114, Invitrogen, Karlsruhe, Germany).
Primary human cells were cultured in RPMI 1640
medium (F1415, Biochrom, Berlin, Germany), supple-
mented with OPI (oxaloacetate, pyruvate, insulin; O-
5003, Sigma, Taufkirchen, Germany), L-glutamine 2 mM
(15140-114, Invitrogen, Karlsruhe, Germany), penicillin
200 U/ml/streptomycin 200 μg/ml (15140-114, Invitro-
gen, Karlsruhe, Germany), and 1× nonessential amino
acids (11140-35, Invitrogen, Karlsruhe, Germany). Before
addition of 10% FCS (S0115, Biochrom, Berlin, Ger-
many), the supplemented medium was ultrafiltered
through a Gambro 2000 column (Gambro, Hechingen,
Germany) in order to remove any inadvertent LPS con-
tamination.
Donors of primary human cells
Primary human cells were obtained from healthy human
volunteers (non-smoker and smoker), from patients with
COPD, or from patients with other lung diseases (TableParticle and Fibre Toxicology 2009, 6:27 http://www.particleandfibretoxicology.com/content/6/1/27
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1). Written informed consent was obtained from each
individual. The protocol was approved by the Ethics Com-
mittee of the Medical School of the Ludwigs-Maximilians-
University (Munich, Germany).
Isolation of peripheral blood mononuclear cells (PBMC), 
enrichment of CD14++ monocytes, and generation of 
monocyte-derived macrophages (MDM)
Human PBMC were isolated from heparinized (10 U/ml)
blood by density gradient centrifugation (Lymphoprep,
1114545, 1.077 g/ml, Oslo, Norway). Cells were directly
used for subsequent isolation of monocytes and cultured
under LPS-free conditions.
For cell enrichment the MACS magnetic separation tech-
nique was used (all columns and reagents from Miltenyi
Biotec, Bergisch-Gladbach, Germany). For isolation of
CD14++ monocytes, PBMC were in a first step depleted of
CD16-positive cells. For this, a total of 20 × 106 cells were
resuspended in 80 μl of PBS containing 25 μl of Anti-
CD16 microbeads (130-045-701). After incubation for 30
min at 4°C cells were washed and resuspended in 1.5 ml
PBS and this was loaded onto a LD column (120-000-
497) that was positioned in a MidiMACS magnet (130-
042-302). Nonadherent cells were recovered and used for
enrichment of CD14++ cells. For this, anti-CD14
microbeads (130-050-201) was diluted 1:5 in PBS and
added to the cells to a final volume of 100 μl. After incu-
bation for 30 min at 4°C cells were washed and resus-
pended in 1.5 ml PBS and this was loaded onto a LS
column (120-000-475). The column was washed five
times with 2 ml PBS each. Cells were recovered from the
column by flushing the column five times with 2 ml PBS
using a plunger. CD14++ cells were washed and resus-
pended in supplemented RPMI 1640 medium (men-
tioned above).
To determine purity of the CD14++ monocytes, a sample
was stained with fluorescein isothiocyanate (FITC)-
labeled anti-CD14 antibody (My4-FITC, 6603511, Coul-
ter, Krefeld, Germany) and phycoerythrin (PE)-labeled
anti-CD16 antibody (Leu11c-PE, Becton-Dickinson, Hei-
delberg, Germany) and measured by flow cytometry.
CD14++ monocytes with a purity of 92% or higher were
used.
For generation of MDM, CD14++-monocytes were culti-
vated in a low-attachment 24-well plate (3473, Costar,
Wiesbaden) and cultured for 5 days with 100 ng/ml M-
CSF (rhM-CSF, kindly provided by Genetics Institute,
Cambridge, Massachusetts, USA).
Sputum induction and processing
Sputum macrophages were collected from healthy human
volunteers and from patients with COPD after informed
consent. The subjects were instructed to mouthwash with
water. Sputum induction was performed by stepwise
inhalations for 10 min each with increasing concentra-
tions of sodium chloride (0.9%, 3%, and 5% in healthy
individuals and 0.9% and 3% in COPD patients), neb-
ulized by an ultrasonic nebulizer (Multisonic LS 290,
Schill, Probstzella, Germany). After inhalation individu-
als were encouraged to cough deeply. Sputum was
coughed into petri dishes (d = 13.5 cm) and processed
immediately.
To homogenize the sputum samples by cleavage of disul-
phide bonds of mucin glycoproteins, four volume parts of
sputolysin reagent (560000, Calbiochem, Bad Soden,
Germany) containing 6.5 mM dithiothreitol and 100 mM
phosphate buffer (pH 7.0) were added. After vortexing
briefly, the mixture was incubated at 37°C and vortexed
every 10 min until the sputum was homogenized, in total
no longer than 50 min. The sputum samples were diluted
with 1 volume PBS (Gibco, Karlsruhe, Germany) and fil-
tered consecutively through a 100 μm and a 40 μm mesh
filter (352360 and 352340, Becton Dickinson, Heidel-
berg, Germany). Cells were then pelleted by centrifuga-
tion for 10 min at 400 × g and 4°C and resuspended in 3
ml PBS. 10 μl packed erythrocytes and 50 μl RosetteSep
Human Monocyte Enrichment Cocktail (15068, CellSys-
tems, St. Katharinen, Germany) were added, which
crosslinks unwanted cells to multiple red blood cells,
forming immunorosettes. After 20 min incubation at
room temperature the sample was layered on the top of
lymphoprep and centrifuged 30 min at 800 × g. The
Table 1: Characteristics of patients and volunteers from which primary human cells were obtained.
number sex age disease and stage
normal healthy 23 12× m, 11× f 42.8 ± 15.4 n.a.
healthy smokers 6 4× m, 2× f 54.5 ± 10.6 n.a.
COPD patients 12 10× m, 2× f 63.9 ± 10.5 4× II, 3× III, 5× IV (Gold)
others (brush biopsies) 7 5× m, 1× f, 1× anonymized* 65.8 ± 11.7* adenocarcinoma, MALT-lymphoma, UIP, sarcoidosis (Gold II), 
COPD (Gold III)*
(*: samples from one patient who underwent brush biopsy was anonymized; f: female; m: male; MALT: mucosa-associated lymphoid tissue; n.a.: not 
applicable; UIP: usual interstitial pneumonia).Particle and Fibre Toxicology 2009, 6:27 http://www.particleandfibretoxicology.com/content/6/1/27
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enriched macrophages were harvested from the plasma
interface.
Brush biopsy of airway epithelial cells
Patients who underwent diagnosic bronchoscopy were
brush biopsied with a sterile single-sheated nylon cytol-
ogy brush (BC-202D-5010, Olympus EndoTherapy,
Hamburg, Germany). Four consecutive brushings from an
intrabronchial area were taken from the proximal part of
one of the main bronchi. Epithelial cells were harvested
from the brush by agitating it in 5 ml of RMPI 1640
medium. After centrifugation cells were lysed in TRI rea-
gent (T-9424, Sigma, Taufkirchen, Germany) and RT-PCR
analysis was performed (see below).
Treatment of cells
For stimulation with lipopolysaccharide (LPS; L-6261,
Sigma, Taufkirchen, Germany) blood cells were incubated
with 10 ng/ml, sputum macrophages with 1 μg/ml for 3 h
each, or remained untreated as control. For particle-stim-
ulation with ultrafine P90 (14 nm in diameter, Degussa,
Frankfurt, Germany) and fine TiO2 (220 nm in diameter,
Degussa, Frankfurt, Germany), cells were incubated for 3
h with 32 μg/ml (each particle) or remained untreated as
control. For particle concentration experiments CD14++
monocytes were incubated with ultrafine P90 for 3 h at
doses of 0.32 μg/ml - 1 mg/ml and 37°C. Using the trypan
blue exclusion assay, cell viability was not found to be
altered by ultrafine P90-treatment at any particle concen-
tration used herein. For time course experiments cells
were incubated for different periods of time (0.5 to 20 h)
with P90 (32 μg/ml). For stimulation with BaP (12780,
Fluka, Taufkirchen, Germany) a 1:50 dilution of BaP-con-
taining liposomes was used. For preparation of liposomes
di-oleyl-phosphoserine (OOPS) and palmitoyloleyl-
phosphocholine (POPC) were dissolved at an OOPS:
POPC ratio of 0.43 in chloroform. BaP in chloroform was
added at different concentrations. Liposomes were gener-
ated by evaporating organic solvent followed by adding
aqueous buffer. Resulting liposomes can be stored up to 4
weeks at 4°C.
Experiments were performed at least in triplicates, using
primary cells from different donors, or cell lines from dif-
ferent passage numbers.
Total RNA isolation and RT-PCR
Polymerase chain reaction (PCR) was performed accord-
ing to the method of Wang and colleagues [42]. Total RNA
was extracted from cells by using TRI Reagent (T-9424,
Sigma, Taufkirchen, Germany) according to the manufac-
turer's instruction. In brief cells were lysed in 200 μl TRI
Reagent and 15 μg tRNA (109517, Roche, Mannheim,
Germany) as carrier were added per sample. After isola-
tion, the RNA was reverse transcribed with oligo(dT) as
primer.
Using the LightCycler system (Roche Diagnostics, Man-
nheim, Germany) according to the manufacturer's
instruction, semi-quantitative PCR were performed with
the following primers:
CYP1A1; 5' primer: 5'-TCT TTC TCT TCC TGG CTA TCC T-
3'
3' primer: 5'-CTG TCT CTT CCC TTC ACT CTT G
CYP1B1; 5' primer: 5'-TGA TGG ACG CCT TTA TCC TCT
C-3'
3' primer: 5'-CAT AAA GGA AGG CCA GGA CAT A-3'
MPO; 5' primer: 5'-TCG GTACCC AGT TCA GGA AGC-3'
3' primer: 5'-CCA GGT TCA ATG CAG GAA GTG T-3'
α-enolase; 5' primer: 5'-GTT AGC AAG AAA CTG AAC GTC
ACA-3'
3' primer: 5'-TGA AGG ACT TGT ACA GGT CAG-3'
3 μl of cDNA were used for amplification in the SYBR
Green format using the LightCycler-FastStart DNA Master
SYBR Green I kit from Roche (2239264, Mannheim, Ger-
many). For PCR analysis, the LightCycler system offers the
advantage of fast and real-time measurement of fluores-
cent signals during amplification. The SYBR Green dye
binds specifically to the minor groove of double stranded
DNA. Fluorescence intensity is measured after each ampli-
fication cycle. During PCR, a doubling of template mole-
cules occurs in each cycle only during the log-linear phase.
Melting curves have been performed after amplification to
ensure that primer dimers did not contribute to the fluo-
rescence intensity of the specific PCR-product. Amplifi-
cates were run out on a 2% agarose gel and bands were
observed on the expected molecular weight. As an internal
control the housekeeping gene α-enolase was amplified.
For analyzing the LightCycler data all samples (tested
gene and housekeeping gene) are processed in the Light-
Cycler software with the same settings (e.g. same thresh-
olds). Cycle number of the housekeeping gene was
subtracted from the corresponding housekeeping gene
and its absolute value was subsequently calculated to the
power of 2. Genes with a higher cycle number than the
corresponding housekeeping gene were plotted to the
negative scale.
Western blot
For Western blot analysis the microsomal fraction was
prepared. After a 32 h incubation with and without 32 μg
P90/ml Calu-3 cells were harvested and the pellet was
resuspended in 4 volumes of hypo-osmolar buffer A (10Particle and Fibre Toxicology 2009, 6:27 http://www.particleandfibretoxicology.com/content/6/1/27
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mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2) in pres-
ence of a protease inhibitor mixture consisting of 10 μg/
ml aprotinin (A-6279, Sigma), 1 mM PMSF (P-7626,
Sigma), 40 μg/ml leupeptin-propionyl (L-3402, Sigma),
20  μg/ml leupeptin-acetate (L-2023, Sigma), 20 μg/ml
antipain (A-6191, Sigma), 20 μg/ml pepstatin A (P-4265,
Sigma), 400 μM ALLN (A-6185, Sigma), and 2 mM DTT
(19474, Merck). The lysates were incubated for 10 min on
ice prior to sonication (8 × 10 sec) and then centrifuged at
3,000 × g for 10 min at 4°C. The resulting supernatant was
centrifuged at first at 12,000 × g for 12 min at 4°C and
then at 25,000 × g for 2 h at 4°C to yield the microsomal
fraction. The microsomal pellet was solubilized in 30 μl of
buffer D (20 mM HEPES pH 7.9, 20% Glycerol, 0.1 M
KCl, 0.05 mM EDTA) in presence of a protease inhibitor
mixture and 0.1% SDS and then stored at -80°C.
Protein concentrations were determined using Bradford
reagent. 10 μg of protein were resolved on a 4-12% Novex
bis-tris gel (NP0329BOX, Invitrogen, Karlsruhe) and
transferred to Hybond-N membranes (LC2001, Invitro-
gen) using a Novex X-Cell II Mini Cell. Membranes were
blocked with blocking buffer (TBS supplemented with 5%
fat-free milk powder (1.15363, Merck) and 0.05%
Tween20 (2323003, Wasserfuhr, Bonn)) and then reacted
with anti CYP1B1 antibody (rabbit polyclonal, CYP1B11-
A, Alpha Diagnostic) over night and anti actin (A-2066,
Sigma) for 1 h. As a second antibody a peroxidase-conju-
gated anti rabbit IgG (A0545, Sigma) was used. Bound
antibody was detected using the ECL kit (RPN2106, Amer-
sham) and membranes then were exposed to Hyper-
film™ECL (RPN3103, Amersham).
Densitometric analysis was performed using NIH ImageJ
software (Version 1.39u, NIH, Bethesda, MD, USA).
Statistics
For statistical analysis of the data, we used the Student's T-
test. Results were considered significant if p < 0.05.
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